Scaling for the Few: How a Patient Foundation is Rewriting Biotech Rules

BOCA RATON, Fla. & COLUMBUS, Ohio – September 29, 2026 – Historically, patient advocacy groups operated on the periphery of the pharmaceutical industry, focusing their efforts on raising awareness and funding early-stage academic research. But as the underlying economics of gene therapy have evolved, a new paradigm has emerged. Today, foundations representing ultra-rare diseases are increasingly acting as sophisticated biotech operators, directly contracting with commercial manufacturers to push experimental therapeutics across the translational "valley of death."

This structural shift in drug development was brought into sharp relief today with the announcement of a development and manufacturing partnership between the TECPR2 Research Foundation and Forge Biologics. The collaboration aims to advance an adeno-associated virus (AAV) gene therapy for TECPR2-related disorder, a fatal, ultra-rare neurodegenerative condition.

Under the agreement, the Ohio-based contract development and manufacturing organization (CDMO) will provide process development, analytical qualification, and the manufacturing of toxicology-grade material. This material will directly support the safety studies required before the therapy can enter human clinical trials.

The Parent-Driven Playbook

For major pharmaceutical companies, ultra-rare monogenic diseases present an intractable economic puzzle. The cost of developing a bespoke gene therapy often exceeds the potential return on investment when the addressable market consists of merely dozens or hundreds of patients globally. Consequently, promising academic research frequently stalls before reaching the clinical trial phase—a funding gap widely known in the industry as the valley of death.

To bridge this gap, organizations like the TECPR2 Research Foundation are deploying a venture-philanthropy model. Founded by families and clinicians, the nonprofit has organized the scientific framework, secured the necessary capital, and is now managing the supply chain for its own therapeutic candidate.

"For our families, this has never simply been a research program. It began with a few children and a commitment to do everything we could to create a path forward for everyone living with TECPR2," said David Ogman, co-founder of the TECPR2 Research Foundation. "That mission has brought together an incredible group of scientists and partners who believe, as we do, that children with ultra-rare diseases deserve the same opportunity for scientific progress as anyone else."

Dr. Michael Kaplan, co-founder of the foundation, echoed the operational necessity of the partnership. "Forge shares that sense of purpose, and we are grateful to have their team and expertise behind us as we take these important steps toward a life-changing treatment."

Overcoming the Manufacturing Bottleneck

Even with adequate funding, the physical production of viral vectors remains one of the most significant bottlenecks in genetic medicine. AAV manufacturing is notoriously complex and expensive, requiring specialized facilities and highly optimized biological processes.

Forge Biologics, a subsidiary of global manufacturing network Ajinomoto Bio-Pharma Services, operates a 200,000-square-foot cGMP facility designed specifically to address this capacity crunch. For the TECPR2 program, the CDMO is leveraging its proprietary FUEL platform, which utilizes HEK293 suspension Ignition Cells and a pEMBR 2.0 adenovirus helper plasmid.

From a bioprocessing perspective, the transition to suspension cell lines is critical. Unlike adherent cultures, which require massive surface areas to grow, suspension cells thrive in large bioreactors, allowing for higher volumetric productivity. For ultra-rare diseases, the goal is not necessarily to produce commercial-scale vats of vector, but rather to execute highly efficient, smaller batches that keep the cost per dose viable.

"When we developed our FUEL™ platform, we set out to improve manufacturing efficiency so treatments could reach more patients, with the needs of both larger patient populations and ultra-rare diseases in mind," said John Maslowski, president and chief executive officer of Forge. "For programs like TECPR2, making the most of every manufacturing run is critical. We are honored to bring our manufacturing technology and expertise to a program that is so deeply personal to the TECPR2 community."

As one bioprocess engineer familiar with the CDMO landscape noted privately, "For ultra-rare indications, the challenge isn't building a bigger bioreactor. It is standardizing the upstream and downstream processes so that the fixed costs of a manufacturing run don't bankrupt a patient-led foundation before they even reach the FDA."

Targeting the Machinery of Cellular Recycling

Behind the manufacturing logistics lies a complex biological target. TECPR2-related disorder, also known as SPG49 or HSAN9, is caused by pathogenic variants in the TECPR2 gene. This gene plays an indispensable role in autophagy—the cellular recycling process responsible for degrading and clearing damaged proteins and organelles.

When autophagy is disrupted by a TECPR2 mutation, toxic cellular waste accumulates. In neurons, which are highly sensitive to this buildup, the result is devastating. Patients suffer from severe developmental delays, intellectual disability, progressive motor deficits, and life-threatening respiratory dysfunction.

The investigational therapy seeks to halt this neurodegeneration by using an AAV vector to deliver a functional, healthy copy of the TECPR2 gene directly into the patient's cells.

To navigate this complex translation, the foundation has partnered with heavyweights in the academic sphere. The scientific program is being spearheaded by AAV gene therapy pioneer Dr. Steven Gray and Dr. Xin Chen at UT Southwestern Medical Center. Dr. Gray's laboratory has a formidable track record in developing gene therapies for rare central nervous system (CNS) disorders, having previously advanced treatments for conditions like Giant Axonal Neuropathy (GAN) and Batten disease. Their involvement provides the program with a battle-tested blueprint for moving a CNS-targeted viral vector from the bench to the clinic.

Navigating Regulatory Realities for the Ultra-Rare

As the TECPR2 program moves into formal toxicology studies utilizing Forge's manufactured material, the foundation must simultaneously prepare for a unique regulatory landscape. The FDA has increasingly recognized that traditional clinical trial designs—which often require large, randomized, placebo-controlled cohorts—are mathematically impossible for ultra-rare diseases.

Instead, regulatory success for programs like this hinges on robust natural history data and the identification of reliable surrogate biomarkers. Because neurodegenerative diseases progress over years, clinical endpoints based purely on observable motor function can delay trial readouts. The FDA is showing a growing willingness to consider biomarkers—such as neurofilament light chain (NfL) to measure axonal damage, or specific biochemical markers of autophagy—as early indicators of therapeutic efficacy.

Furthermore, the route of administration for CNS gene therapies introduces distinct safety considerations. Direct delivery to the central nervous system, often required to bypass the blood-brain barrier, necessitates rigorous preclinical biodistribution studies to ensure the viral vector reaches the target neurons without triggering severe localized immune responses.

Initiatives like the NIH's Bespoke Gene Therapy Consortium (BGTC) are currently working to standardize these regulatory and manufacturing pathways for ultra-rare diseases. In the meantime, patient foundations are not waiting for the system to fix itself. By assembling specialized academic researchers and commercial manufacturing partners, the TECPR2 Research Foundation is actively forging a viable path forward, demonstrating how grassroots urgency can successfully orchestrate complex biopharmaceutical development.